Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2002 Nov;61(Suppl 2):ii96–ii99. doi: 10.1136/ard.61.suppl_2.ii96

Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases

R Wilder
PMCID: PMC1766704  PMID: 12379637

Full Text

The Full Text of this article is available as a PDF (74.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albelda S. M., Mette S. A., Elder D. E., Stewart R., Damjanovich L., Herlyn M., Buck C. A. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res. 1990 Oct 15;50(20):6757–6764. [PubMed] [Google Scholar]
  2. Badger A. M., Blake S., Kapadia R., Sarkar S., Levin J., Swift B. A., Hoffman S. J., Stroup G. B., Miller W. H., Gowen M. Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum. 2001 Jan;44(1):128–137. doi: 10.1002/1529-0131(200101)44:1<128::AID-ANR17>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  3. Beglova Natalia, Blacklow Stephen C., Takagi Junichi, Springer Timothy A. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nat Struct Biol. 2002 Apr;9(4):282–287. doi: 10.1038/nsb779. [DOI] [PubMed] [Google Scholar]
  4. Boettiger D., Huber F., Lynch L., Blystone S. Activation of alpha(v)beta3-vitronectin binding is a multistage process in which increases in bond strength are dependent on Y747 and Y759 in the cytoplasmic domain of beta3. Mol Biol Cell. 2001 May;12(5):1227–1237. doi: 10.1091/mbc.12.5.1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Boettiger D., Lynch L., Blystone S., Huber F. Distinct ligand-binding modes for integrin alpha(v)beta(3)-mediated adhesion to fibronectin versus vitronectin. J Biol Chem. 2001 Jun 21;276(34):31684–31690. doi: 10.1074/jbc.M103997200. [DOI] [PubMed] [Google Scholar]
  6. Bouvard D., Brakebusch C., Gustafsson E., Aszódi A., Bengtsson T., Berna A., Fässler R. Functional consequences of integrin gene mutations in mice. Circ Res. 2001 Aug 3;89(3):211–223. doi: 10.1161/hh1501.094874. [DOI] [PubMed] [Google Scholar]
  7. Brooks P. C., Clark R. A., Cheresh D. A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994 Apr 22;264(5158):569–571. doi: 10.1126/science.7512751. [DOI] [PubMed] [Google Scholar]
  8. Brooks P. C., Montgomery A. M., Rosenfeld M., Reisfeld R. A., Hu T., Klier G., Cheresh D. A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994 Dec 30;79(7):1157–1164. doi: 10.1016/0092-8674(94)90007-8. [DOI] [PubMed] [Google Scholar]
  9. Brooks P. C., Strömblad S., Klemke R., Visscher D., Sarkar F. H., Cheresh D. A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 1995 Oct;96(4):1815–1822. doi: 10.1172/JCI118227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Carmeliet Peter. Integrin indecision. Nat Med. 2002 Jan;8(1):14–16. doi: 10.1038/nm0102-14. [DOI] [PubMed] [Google Scholar]
  11. Carron C. P., Meyer D. M., Pegg J. A., Engleman V. W., Nickols M. A., Settle S. L., Westlin W. F., Ruminski P. G., Nickols G. A. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res. 1998 May 1;58(9):1930–1935. [PubMed] [Google Scholar]
  12. Chellaiah M., Kizer N., Silva M., Alvarez U., Kwiatkowski D., Hruska K. A. Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength. J Cell Biol. 2000 Feb 21;148(4):665–678. doi: 10.1083/jcb.148.4.665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cheresh David A., Stupack Dwayne G. Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat Med. 2002 Mar;8(3):193–194. doi: 10.1038/nm0302-193. [DOI] [PubMed] [Google Scholar]
  14. Clover J., Dodds R. A., Gowen M. Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture. J Cell Sci. 1992 Sep;103(Pt 1):267–271. doi: 10.1242/jcs.103.1.267. [DOI] [PubMed] [Google Scholar]
  15. Deryugina E. I., Bourdon M. A., Jungwirth K., Smith J. W., Strongin A. Y. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer. 2000 Apr 1;86(1):15–23. doi: 10.1002/(sici)1097-0215(20000401)86:1<15::aid-ijc3>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  16. Deryugina E. I., Ratnikov B., Monosov E., Postnova T. I., DiScipio R., Smith J. W., Strongin A. Y. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res. 2001 Feb 15;263(2):209–223. doi: 10.1006/excr.2000.5118. [DOI] [PubMed] [Google Scholar]
  17. Eliceiri B. P., Cheresh D. A. The role of alphav integrins during angiogenesis. Mol Med. 1998 Dec;4(12):741–750. [PMC free article] [PubMed] [Google Scholar]
  18. Eliceiri B. P., Cheresh D. A. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999 May;103(9):1227–1230. doi: 10.1172/JCI6869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Felding-Habermann B., O'Toole T. E., Smith J. W., Fransvea E., Ruggeri Z. M., Ginsberg M. H., Hughes P. E., Pampori N., Shattil S. J., Saven A. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1853–1858. doi: 10.1073/pnas.98.4.1853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Goldring S. R., Gravallese E. M. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol. 2000 May;12(3):195–199. doi: 10.1097/00002281-200005000-00006. [DOI] [PubMed] [Google Scholar]
  21. Gottschalk Kay E., Günther Robert, Kessler Horst. A three-state mechanism of integrin activation and signal transduction for integrin alpha(v)beta(3). Chembiochem. 2002 May 3;3(5):470–473. doi: 10.1002/1439-7633(20020503)3:5<470::AID-CBIC470>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  22. Gravallese E. M., Goldring S. R. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum. 2000 Oct;43(10):2143–2151. doi: 10.1002/1529-0131(200010)43:10<2143::AID-ANR1>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  23. Helfrich M. H., Nesbitt S. A., Horton M. A. Integrins on rat osteoclasts: characterization of two monoclonal antibodies (F4 and F11) to rat beta 3. J Bone Miner Res. 1992 Mar;7(3):345–351. doi: 10.1002/jbmr.5650070315. [DOI] [PubMed] [Google Scholar]
  24. Hermann P., Armant M., Brown E., Rubio M., Ishihara H., Ulrich D., Caspary R. G., Lindberg F. P., Armitage R., Maliszewski C. The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23. J Cell Biol. 1999 Feb 22;144(4):767–775. doi: 10.1083/jcb.144.4.767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hodivala-Dilke K. M., McHugh K. P., Tsakiris D. A., Rayburn H., Crowley D., Ullman-Culleré M., Ross F. P., Coller B. S., Teitelbaum S., Hynes R. O. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999 Jan;103(2):229–238. doi: 10.1172/JCI5487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hynes R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992 Apr 3;69(1):11–25. doi: 10.1016/0092-8674(92)90115-s. [DOI] [PubMed] [Google Scholar]
  27. Inoue M., Ross F. P., Erdmann J. M., Abu-Amer Y., Wei S., Teitelbaum S. L. Tumor necrosis factor alpha regulates alpha(v)beta5 integrin expression by osteoclast precursors in vitro and in vivo. Endocrinology. 2000 Jan;141(1):284–290. doi: 10.1210/endo.141.1.7285. [DOI] [PubMed] [Google Scholar]
  28. Johnson B. A., Haines G. K., Harlow L. A., Koch A. E. Adhesion molecule expression in human synovial tissue. Arthritis Rheum. 1993 Feb;36(2):137–146. doi: 10.1002/art.1780360203. [DOI] [PubMed] [Google Scholar]
  29. Koch A. E. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis. 2000 Nov;59 (Suppl 1):i65–i71. doi: 10.1136/ard.59.suppl_1.i65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. McHugh K. P., Hodivala-Dilke K., Zheng M. H., Namba N., Lam J., Novack D., Feng X., Ross F. P., Hynes R. O., Teitelbaum S. L. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest. 2000 Feb;105(4):433–440. doi: 10.1172/JCI8905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Miller WH, Keenan RM, Willette RN, Lark MW. Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor). Drug Discov Today. 2000 Sep;5(9):397–408. doi: 10.1016/s1359-6446(00)01545-2. [DOI] [PubMed] [Google Scholar]
  32. Nakamura I., Pilkington M. F., Lakkakorpi P. T., Lipfert L., Sims S. M., Dixon S. J., Rodan G. A., Duong L. T. Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. J Cell Sci. 1999 Nov;112(Pt 22):3985–3993. doi: 10.1242/jcs.112.22.3985. [DOI] [PubMed] [Google Scholar]
  33. Nesbitt S., Nesbit A., Helfrich M., Horton M. Biochemical characterization of human osteoclast integrins. Osteoclasts express alpha v beta 3, alpha 2 beta 1, and alpha v beta 1 integrins. J Biol Chem. 1993 Aug 5;268(22):16737–16745. [PubMed] [Google Scholar]
  34. Petrow P. K., Hummel K. M., Schedel J., Franz J. K., Klein C. L., Müller-Ladner U., Kriegsmann J., Chang P. L., Prince C. W., Gay R. E. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum. 2000 Jul;43(7):1597–1605. doi: 10.1002/1529-0131(200007)43:7<1597::AID-ANR25>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  35. Pfaff M., Jurdic P. Podosomes in osteoclast-like cells: structural analysis and cooperative roles of paxillin, proline-rich tyrosine kinase 2 (Pyk2) and integrin alphaVbeta3. J Cell Sci. 2001 Aug;114(Pt 15):2775–2786. doi: 10.1242/jcs.114.15.2775. [DOI] [PubMed] [Google Scholar]
  36. Reinholt F. P., Hultenby K., Oldberg A., Heinegård D. Osteopontin--a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4473–4475. doi: 10.1073/pnas.87.12.4473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Reynolds Louise E., Wyder Lorenza, Lively Julie C., Taverna Daniela, Robinson Stephen D., Huang Xiaozhu, Sheppard Dean, Hynes Richard O., Hodivala-Dilke Kairbaan M. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002 Jan;8(1):27–34. doi: 10.1038/nm0102-27. [DOI] [PubMed] [Google Scholar]
  38. Rupp P. A., Little C. D. Integrins in vascular development. Circ Res. 2001 Sep 28;89(7):566–572. doi: 10.1161/hh1901.097747. [DOI] [PubMed] [Google Scholar]
  39. Shinar D. M., Schmidt A., Halperin D., Rodan G. A., Weinreb M. Expression of alpha v and beta 3 integrin subunits in rat osteoclasts in situ. J Bone Miner Res. 1993 Apr;8(4):403–414. doi: 10.1002/jbmr.5650080404. [DOI] [PubMed] [Google Scholar]
  40. Soldi R., Mitola S., Strasly M., Defilippi P., Tarone G., Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999 Feb 15;18(4):882–892. doi: 10.1093/emboj/18.4.882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Storgard C. M., Stupack D. G., Jonczyk A., Goodman S. L., Fox R. I., Cheresh D. A. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest. 1999 Jan;103(1):47–54. doi: 10.1172/JCI3756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Stupack D. G., Puente X. S., Boutsaboualoy S., Storgard C. M., Cheresh D. A. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol. 2001 Oct 29;155(3):459–470. doi: 10.1083/jcb.200106070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Teitelbaum S. L. Bone resorption by osteoclasts. Science. 2000 Sep 1;289(5484):1504–1508. doi: 10.1126/science.289.5484.1504. [DOI] [PubMed] [Google Scholar]
  44. Teitelbaum S. L. Osteoclasts, integrins, and osteoporosis. J Bone Miner Metab. 2000;18(6):344–349. doi: 10.1007/s007740070007. [DOI] [PubMed] [Google Scholar]
  45. Tsou R., Isik F. F. Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells. Mol Cell Biochem. 2001 Aug;224(1-2):81–89. doi: 10.1023/a:1011947301849. [DOI] [PubMed] [Google Scholar]
  46. Walsh D. A., Wade M., Mapp P. I., Blake D. R. Focally regulated endothelial proliferation and cell death in human synovium. Am J Pathol. 1998 Mar;152(3):691–702. [PMC free article] [PubMed] [Google Scholar]
  47. Weerasinghe D., McHugh K. P., Ross F. P., Brown E. J., Gisler R. H., Imhof B. A. A role for the alphavbeta3 integrin in the transmigration of monocytes. J Cell Biol. 1998 Jul 27;142(2):595–607. doi: 10.1083/jcb.142.2.595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Wu H., Beuerlein G., Nie Y., Smith H., Lee B. A., Hensler M., Huse W. D., Watkins J. D. Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6037–6042. doi: 10.1073/pnas.95.11.6037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Xiong J. P., Stehle T., Diefenbach B., Zhang R., Dunker R., Scott D. L., Joachimiak A., Goodman S. L., Arnaout M. A. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science. 2001 Sep 6;294(5541):339–345. doi: 10.1126/science.1064535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Xiong Jian-Ping, Stehle Thilo, Zhang Rongguang, Joachimiak Andrzej, Frech Matthias, Goodman Simon L., Arnaout M. Amin. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science. 2002 Mar 7;296(5565):151–155. doi: 10.1126/science.1069040. [DOI] [PubMed] [Google Scholar]
  51. Yumoto Kenji, Ishijima Muneaki, Rittling Susan R., Tsuji Kunikazu, Tsuchiya Yoko, Kon Shigeyuki, Nifuji Akira, Uede Toshimitsu, Denhardt David T., Noda Masaki. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4556–4561. doi: 10.1073/pnas.052523599. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES